Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Verastem ( (VSTM) ) has provided an update.
On December 19, 2025, Verastem’s chief operating officer Matthew Ros separated from the company under a negotiated separation agreement that provides for nine months of salary continuation, COBRA-related support and a pro-rated bonus, as the biopharma group streamlines its operational structure and redistributes his responsibilities across the executive team. The move follows a December 15, 2025 leadership reshuffle in which long-time board member John Johnson was elevated to chairman and lead director Michael Kauffman was appointed president of development, formalizing a strategic transition meant to support the commercial rollout of AVMAPKI FAKZYNJA CO-PACK and the advancing clinical pipeline, including completion of additional patient enrollment in the RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC, a key study for securing and potentially broadening the product’s market positioning.
The most recent analyst rating on (VSTM) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
Verastem’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative equity. However, positive technical indicators and recent corporate events, such as the $75M private placement, provide some optimism for future growth. Valuation remains constrained by negative earnings, but strategic initiatives and product development efforts could drive improvements. The stock represents a speculative opportunity, with potential upside if financial health and operational efficiencies improve.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem Oncology is a Boston-based biopharmaceutical company focused on developing and commercializing targeted therapies for RAS/MAPK pathway-driven cancers. Its lead products include the AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib approved in the United States since May 8, 2025, for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The company is also advancing multiple Phase 3 and earlier-stage trials evaluating this combination in recurrent LGSOC, advanced pancreatic cancer and KRAS-mutant non-small cell lung cancer.
Average Trading Volume: 2,230,085
Technical Sentiment Signal: Hold
Current Market Cap: $599.5M
See more insights into VSTM stock on TipRanks’ Stock Analysis page.